{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T10:34:32Z","timestamp":1774780472047,"version":"3.50.1"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:p>The literature assessing the addition of long-acting injectable antipsychotics (LAIs) to clozapine is limited. The aim of this retrospective study was to determine the safety and effectiveness of adding LAIs to clozapine in patients with treatment-resistant schizophrenia (TRS). Patients aged 18\u201365\u2009years with TRS, who were treated with first-generation (FGA-LAIs) and second-generation (SGA-LAIs) for at least 1\u2009year after clozapine use, were included retrospectively by registration system scanning. Effectiveness measures included relapses and hospitalizations and days of hospitalization. Safety outcomes included levels of neutrophils, fasting blood sugar, total cholesterol, triglycerides, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and prolactin. The data of 29 patients who met the study criteria were evaluated. The numbers and days of hospitalizations and the numbers of relapses significantly decreased after LAI addition. Comparisons of the neutrophil counts and the total cholesterol, triglyceride, HDL, LDL, prolactin, and fasting blood glucose levels as safety indicators of the clozapine and LAI combination revealed no statistically significant change in these values before and after LAI addition. Adding LAIs to clozapine is apparently well tolerated in patients with TRS and may have a positive effect on the course of the disease.<\/jats:p>","DOI":"10.1097\/yic.0000000000000336","type":"journal-article","created":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T08:01:11Z","timestamp":1602489671000},"page":"30-33","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":19,"title":["The effects of adding long-acting injectable antipsychotic drugs to clozapine on relapse and hospitalization in patients with treatment-resistant schizophrenia: a mirror-image retrospective study"],"prefix":"10.1097","volume":"36","author":[{"given":"Ali Metehan","family":"Caliskan","sequence":"first","affiliation":[{"name":"Department of Psychiatry, University of Health Sciences, Konya Education and Research Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munir","family":"Karaaslan","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Health Sciences, Konya Education and Research Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikbal","family":"Inanli","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Health Sciences, Konya Education and Research Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sila","family":"Caliskan","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Konya Beyhekim State Hospital, Konya"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet","family":"Arslan","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Kirklareli Babaeski State Hospital, Kirklareli"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismet","family":"Esra Cicek","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Health Sciences, Konya Education and Research Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Eren","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Bolu Abant Izzet Baysal University, Bolu, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,10,8]]},"reference":[{"key":"R1-20250802","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/YIC.0000000000000125","article-title":"Factors associated with relapse in schizophrenia despite adherence to long-acting injectable antipsychotic therapy.","volume":"31","author":"Alphs","year":"2016","journal-title":"Int Clin Psychopharmacol"},{"key":"R3-20250802","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2165\/00019053-200826020-00005","article-title":"The burden of schizophrenia on caregivers: a review.","volume":"26","author":"Awad","year":"2008","journal-title":"Pharmacoeconomics"},{"key":"R4-20250802","first-page":"143","article-title":"Efficacy and safety of long-acting injectable risperidone in maintenance phase of bipolar and schizoaffective disorder.","volume":"37","author":"Benabarre","year":"2008","journal-title":"Actas Esp Psiquiatr"},{"key":"R5-20250802","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/15622970500483177","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia.","volume":"7","author":"Falkai","year":"2006","journal-title":"World J Biol Psychiatry"},{"key":"R6-20250802","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1176\/appi.ajp.2017.16091016","article-title":"The long-term effects of antipsychotic medication on clinical course in schizophrenia.","volume":"174","author":"Goff","year":"2017","journal-title":"Am J Psychiatry"},{"key":"R7-20250802","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.","volume":"45","author":"Kane","year":"1988","journal-title":"Arch Gen Psychiatry"},{"key":"R23-20250802","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1177\/0269881109348174","article-title":"The combined use of risperidone long-acting injection and clozapine in patients with schizophrenia non-adherent to clozapine: A case series.","volume":"24","author":"Kim","year":"2010","journal-title":"Journal of Psychopharmacology"},{"key":"R8-20250802","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1093\/schbul\/sbx090","article-title":"Effectiveness of long-acting injectable vs oral antipsychotics in patients with schizophrenia: a meta-analysis of prospective and retrospective cohort studies.","volume":"44","author":"Kishimoto","year":"2018","journal-title":"Schizophr Bull"},{"key":"R9-20250802","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(12)60239-6","article-title":"Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis.","volume":"379","author":"Leucht","year":"2012","journal-title":"Lancet"},{"key":"R10-20250802","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1055\/s-0034-1390469","article-title":"Antipsychotic agents used to augment clozapine during long-term inpatient hospitalizations.","volume":"47","author":"Leung","year":"2014","journal-title":"Pharmacopsychiatry"},{"key":"R11-20250802","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S1726-4901(09)70254-0","article-title":"Comparison of time to rehospitalization among schizophrenic patients discharged on typical antipsychotics, clozapine or risperidone.","volume":"69","author":"Lin","year":"2006","journal-title":"J Chin Med Assoc"},{"key":"R12-20250802","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3371\/CSRP.6.3.5","article-title":"Clozapine: balancing safety with superior antipsychotic efficacy.","volume":"6","author":"Meltzer","year":"2012","journal-title":"Clin Schizophr Relat Psychoses"},{"key":"R13-20250802","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/JCP.0000000000001205","article-title":"Lurasidone improves psychopathology and cognition in treatment-resistant schizophrenia.","volume":"40","author":"Meltzer","year":"2020","journal-title":"J Clin Psychopharmacol"},{"key":"R14-20250802","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/YIC.0000000000000285","article-title":"Long-term effects of paliperidone palmitate on hospital stay and treatment continuation.","volume":"34","author":"Pappa","year":"2019","journal-title":"Int Clin Psychopharmacol"},{"key":"R15-20250802","first-page":"9","article-title":"Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia.","volume":"3","author":"Peng","year":"2011","journal-title":"Clinicoecon Outcomes Res"},{"key":"R16-20250802","doi-asserted-by":"crossref","first-page":"189","DOI":"10.4088\/JCP.v59n0408","article-title":"Psychiatric hospital utilization in patients treated with clozapine for up to 4.5 years in a state mental health care system.","volume":"59","author":"Reid","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"R17-20250802","doi-asserted-by":"crossref","first-page":"512047","DOI":"10.1100\/2012\/512047","article-title":"Auditing clinical outcomes after introducing off-licence prescribing of atypical antipsychotic melperone for patients with treatment refractory schizophrenia.","volume":"2012","author":"R\u00f6hricht","year":"2012","journal-title":"Scientificworldjournal"},{"key":"R18-20250802","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.schres.2019.10.037","article-title":"Predicting relapse with residual symptoms in schizophrenia: a secondary analysis of the PROACTIVE trial.","volume":"215","author":"Saito","year":"2020","journal-title":"Schizophr Res"},{"key":"R19-20250802","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.schres.2017.01.036","article-title":"Clozapine and long-acting injectable antipsychotic combination: A retrospective one-year mirror-image study.","volume":"188","author":"Souaiby","year":"2017","journal-title":"Schizophr Res"},{"key":"R20-20250802","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0140-6736(09)60742-X","article-title":"11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).","volume":"374","author":"Tiihonen","year":"2009","journal-title":"Lancet"},{"key":"R21-20250802","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1517\/14656566.2011.528200","article-title":"Pharmacotherapy for treatment-refractory schizophrenia.","volume":"12","author":"Van Sant","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"R22-20250802","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/15622970701530917","article-title":"A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone.","volume":"9","author":"Vieta","year":"2008","journal-title":"World J Biol Psychiatry"}],"container-title":["International Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/YIC.0000000000000336","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T18:06:13Z","timestamp":1754157973000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/YIC.0000000000000336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,8]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/yic.0000000000000336","relation":{},"ISSN":["0268-1315"],"issn-type":[{"value":"0268-1315","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10,8]]}}}